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Letters to the Editorand only for patients presenting with a
coagulopathy as confirmed by rota-
tional thromboelastometric analysis.
Ideally, the lowest dose capable
of correcting the coagulopathy should
be given, avoiding a hypercoagulable
state and thus thromboembolic events.
Adopting this protocol avoids placing
patients with a surgical cause of
bleeding at an unjustified risk of
thromboembolism and reserves rFVIIa
for thosewho truly need it.
In conclusion, rFVIIa represents
a treatment with its own specific indi-
cations, and we should not consider it
as an alternative to reexploration in
cardiac surgery. Indeed, the two are
‘‘horses for courses.’’
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WeappreciateTarzia andcolleagues’
letter regarding our article.1 They take
exception to comparing reexploration
with pharmacologic management us-
ing recombinant activated factor VII
(rFVIIa) in the intensive care unit be-
cause the source of bleeding is not
known. They also elucidate a well–
thought out algorithm for the manage-
ment of postoperative bleeding.
Our initial experience with rFVIIa
was in the operating room, where we
found it to be highly effective at con-
trolling intraoperative bleeding and
to reduce the incidence of packing
and delayed closure for hemostasis.2
We developed criteria for correction
of coagulopathy (including platelet
count, prothrombin time, partial
thromboplastin time, and fibrinogen
levels), acid–base status, temperature,
and ionized calcium levels before the
administration of rFVIIa. We found
that patients who continued to bleed
despite correction of these variables
responded quickly to rFVIIa.
All intensive care unit patients in our
current study had undergone similar
evaluations in the operating room and
were considered not to have surgical
bleeding. Unfortunately, the source of
significant bleeding in the intensive
care unit is always unknown, and this
is the clinical conundrum our study at-
tempted to address. In this study, we
found 1 case of surgical bleeding out
of the 12 patients who received rFVIIa.
This is substantially lower than the
50% quoted by Tarzia and colleagues.
This emphasizes the importance of
having a well–thought out algorithm
for the management of bleeding. Ours
begins by defining significant bleeding
as 3 mL/kg/h for 2 or more consecutive
hours. Correction of the previously
mentioned variables is accomplished
as early as possible. Hemothorax and
pericardial tamponade are considered
indications for reoperation. Finally,
the attending surgeon’s index of suspi-
cion for surgical bleeding is the final
determinant of therapy. As we hadof Thoracic and Cardiovascular Surgerpreviously observed in the operating
room, bleeding intensive care unit pa-
tients with corrected coagulation fac-
tors, temperature, ionized calcium,
and acidosis quickly responded to
rFVIIa.This suggests thatwe are not ca-
pable of measuring a clinically signifi-
cant coagulation deficiency. Perhaps
rotational thromboelastometry will be
able to shed light on these difficult pa-
tients. Rotational thromboelastometry
was only recently approved by the
Food and Drug Administration in 2010
(after our study period), and further-
more only 2 of the 4 reagents described
by Tarzia and colleagues, INTEM and
HEPTEM, have been approved.
We anxiously await new tools for
the diagnosis and treatment of postop-
erative coagulopathic bleeding. It is
important that they be incorporated
into a well-designed and well–thought
out algorithm for the treatment of
postoperative bleeding.
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To the Editor:
We read with great interest the re-
cent published paper by Shi andy c Volume 142, Number 6 1589
Letters to the Editorcolleagues.1 They introduced a case
series with the use of innominate can-
nulation during repair of Stanford type
A aortic dissection with ascending
aorta and hemiarch replacement com-
bined with stent–graft elephant trunk.
We congratulate them for their excel-
lent clinical results and also would
like to discuss a few questions regard-
ing cannulation during antegrade ce-
rebral perfusion (ACP).
The combined use of ACP with hy-
pothermic circulatory arrest (HCA) is
widely accepted as a routine means of
protecting the brain during complex
aortic arch reconstruction; however,
the risks of brain complications re-
lated to HCA and extensive ACP
times also remain a substantial burden
in aortic arch construction. Moreover,
technical issues relating to the use of
ACP during HCA, such as cannulation
sites and types for ACP, unilateral per-
fusion or bilateral perfusion, and the
flow rate and blood pressure used to
selectively perfuse the brain, are still
uncertain. ACP has become recog-
nized as an important mode for arch
replacement and can be performed
in several different ways: unilateral
cerebral perfusion through the right
axillary artery or the right brachial ar-
tery, or the innominate artery. It is well
documented that unilateral cerebral
perfusion through the right axillary ar-
tery by direct cannulation has been
successfully used in a majority of
heart centers.2 In a previous letter
published elsewhere,3 we discussed
the benefits and risks with Xu, whose
group used a side vascular graft to
perfuse the innominate artery in
conjunction with the use of HCA dur-
ing aortic arch surgery. Shi and col-
leagues1 also summarized benefits
with cannulation at the innominate
artery site relative to right axillary
artery cannulation: (1) No additional
incision is needed. (2) The same tech-
nique and same size of cannula are
used as in ascending aortic cannula-
tion. (3) Cerebral perfusion pressure
can be monitored continuously with
a right arterial line.1590 The Journal of Thoracic andRelative to Xu’s method, cannula-
tion at the innominate artery has
more limitations. First, cannulation
at the innominate artery avoids the
additional incision, but you may
have another cannula in your surgi-
cal field. Although the innominate
artery is larger than the right axillary
artery, it is shorter; moreover, you
have to choose a cannula with
a curved tip, because the tip of the
cannula should be adjusted in direc-
tion at least twice during the proce-
dure. Adjustment of the direction of
the cannula may cause damage to
the artery.4 A cannula with a curved
tip generates greater pressure drops
and may cause more blood damage.
Moreover, as we mentioned in our
previous letter,3 we still think that
there is a potential risk when the in-
nominate artery is used to perfuse the
brain. When the innominate artery is
used, blood flow distribution may de-
pend on the resistance of the right
axillary artery and the left common
carotid artery. Our concern is that if
the resistance of the right axillary ar-
tery decreases or increases, this may
result in malperfusion to the brain.
Although this has not been widely
recognized in the study of ACP
flow during HCA, both overperfu-
sion and underperfusion have been
shown to be detrimental to the brain.
In our previous research, when the
ACP (unilateral cerebral perfusion
through the right axillary artery by
direct cannulation) flow was lower
than 10 mL/kg, transcranial Doppler
ultrasonography could not detect the
signal of blood flow in the middle ce-
rebral artery.5 We think that nomatter
which way is used during arctic arch
surgery, it is most important that we
knowwhether the brain is at a suitable
ratio of blood flow and oxygen con-
sumption. To achieve this purpose,
the best way to monitor the brain
status is by combining transcranial
Doppler ultrasonography with near-
infrared spectrography during this
procedure, not relying on pressure
alone.Cardiovascular Surgery c December 20Bingyang Ji, MD
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doi:10.1016/j.jtcvs.2011.07.064Reply to the Editor:
We thank Ji and colleagues for their
insightful comments on the technique
of innominate artery cannulation dur-
ing surgery to correct Stanford type
A aortic dissection as described in
our recently published article.1
Although one more cannula is in the
surgical field when the innominate ar-
tery cannulation technique is used, we
do not think that this cannula will add
any difficulty to the operation. Gentle
adjustment of the direction of the
cannula by an experienced surgeon
will do no damage to the artery. In Ji
and colleagues’ opinion, a cannula
with a curved tip may generate higher
pressure drop and cause more blood
damage. In contrast, we think that the11
